Imjudo is a CTLA-4 inhibitor—the same MoA as BMY’s Yervoy. The FDA approval is for a combination regimen consisting of a single dose of Imjudo followed by monthly doses of Imfinzi (AZN’s PD-L1 inhibitor). This regimen was worked out after considerable trial and error by AZN.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.